Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Finance
    3. >Contract drug manufacturer Lonza forecasts slower sales growth for 2026
    Finance

    Contract Drug Manufacturer Lonza Forecasts Slower Sales Growth for 2026

    Published by Global Banking & Finance Review®

    Posted on January 28, 2026

    2 min read

    Last updated: January 28, 2026

    Add as preferred source on Google
    Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:Sales growthMarket analysisInvestment opportunities

    Quick Summary

    Lonza predicts 11-12% sales growth for its CDMO business by 2026, with higher growth in the first half and profit margins above 32%.

    Lonza Anticipates Slower Sales Growth in 2026 for CDMO Business

    Lonza's Sales Growth Forecast for 2026

    Jan 28 (Reuters) - Lonza, the world's largest contract drug manufacturer, on Wednesday set 2026 targets for its contract development and manufacturing organization (CDMO) business, expecting slower sales growth of 11% to 12% at constant exchange rates and for its core profit margin to expand to above 32% of sales.

    Sales Growth Expectations

    The Swiss company added it expected sales growth to be higher in the first half of 2026 than in the second half.

    Core Profit Margin Insights

    In 2025, the CDMO business, which was split off from the capsule and health ingredients (CHI) business which Lonza is planning to sell, saw its sales grow 21.7% in constant currency to 6.5 billion Swiss francs ($8.5 billion).

    Dividend Proposal Details

    Analysts were expecting sales in the core business to grow 20.7% to 6.49 billion francs, a poll compiled by Vara showed.

    Lonza said sales growth was driven by a higher than expected contribution from its Vacaville site in California and good momentum across its mammalian, bioconjugates, small molecules, drug product and bioscience technology platforms.

    The Basel-based group said its core profit margin, or ratio of earnings before interest, taxes, depreciation and amortisation to sales in the continuing business, was 31.6% in 2025, above the 30.7% expected by analysts.

    The company also said it would propose a dividend of 5 francs per share, 25% higher than what was paid last year.

    ($1 = 0.7654 Swiss francs)

    (Reporting by Bernadette Hogg and Orest Dovhan in Gdansk, editing by Milla Nissi-Prussak)

    Table of Contents

    • Lonza's Sales Growth Forecast for 2026
    • Sales Growth Expectations
    • Core Profit Margin Insights
    • Dividend Proposal Details

    Key Takeaways

    • •Lonza forecasts 11-12% sales growth for its CDMO business by 2026.
    • •Core profit margins are expected to exceed 32% of sales.
    • •Sales growth is anticipated to be higher in the first half of 2026.
    • •Lonza is the world's largest contract drug manufacturer.
    • •The forecast is set at constant exchange rates.

    Frequently Asked Questions about Contract drug manufacturer Lonza forecasts slower sales growth for 2026

    1What is sales growth?

    Sales growth refers to the increase in revenue generated by a company over a specific period, typically expressed as a percentage. It indicates the company's ability to expand its business and attract more customers.

    2What is a profit margin?

    Profit margin is a financial metric that shows the percentage of revenue that exceeds the costs of goods sold (COGS). It reflects how efficiently a company is managing its expenses relative to its sales.

    3
    What is a financial projection?

    A financial projection is an estimate of future financial outcomes for a company based on historical data, market trends, and expected economic conditions. It helps businesses plan and allocate resources effectively.

    More from Finance

    Explore more articles in the Finance category

    Image for Israel strikes Tehran as Trump says US negotiating to end war
    Israel Strikes Tehran as Trump Says US Negotiating to End War
    Image for South Korea, Germany exposed to rare earths shortage, Australia's Arafura says
    South Korea, Germany Exposed to Rare Earths Shortage, Australia's Arafura Says
    Image for Currency markets drift as traders sceptical of US efforts to end Iran war
    Currency Markets Drift as Traders Sceptical of US Efforts to End Iran War
    Image for Stocks bounce and oil retreats on Mideast ceasefire reports
    Stocks Bounce and Oil Retreats on Mideast Ceasefire Reports
    Image for Equinor CEO says EU unlikely to increase Russian gas imports
    Equinor CEO Says EU Unlikely to Increase Russian Gas Imports
    Image for Openreach taps Google AI to speed fibre rollout, cut emissions
    Openreach Taps Google AI to Speed Fibre Rollout, Cut Emissions
    Image for UK consumer sentiment falls as Iran war rages, KPMG says
    UK Consumer Sentiment Falls as Iran War Rages, Kpmg Says
    Image for US oil prices fall on prospect of Middle East ceasefire easing supply disruption
    US Oil Prices Fall on Prospect of Middle East Ceasefire Easing Supply Disruption
    Image for Lamborghinis stranded in Sri Lanka as war disrupts Asia's used-car trade 
    Lamborghinis Stranded in Sri Lanka as War Disrupts Asia's Used-Car Trade 
    Image for Britain pilots social media bans, time limits and curfews for children
    Britain Pilots Social Media Bans, Time Limits and Curfews for Children
    Image for UK's Starmer, Saudi crown prince discussed ongoing Middle East conflict, Downing Street says
    UK's Starmer, Saudi Crown Prince Discussed Ongoing Middle East Conflict, Downing Street Says
    Image for Grifols approves IPO of its US biopharma business
    Grifols Approves IPO of Its US Biopharma Business
    View All Finance Posts
    Previous Finance PostJera Considering How to Utilise Gas Portfolio Beyond Japan, Says CEO
    Next Finance PostMorning Bid: Trump's Talk Downs the Dollar